The radiochemistry core will continue to provide the radiopharmaceuticals, radiopharmaceutical quality control, metabolite analysis and regulatory documentation required by the projects to fulfill the goals of the research described in this application.
The specific aims are to produce [11]C, [18]F, and [15]O, and to use these radionuclides to make the radiopharmaceuticals: 2-[[11]C]-thymidine;[[11]C]-verapamil;[[11]C]-doxorubicin;[[11]C]-carbon dioxide;[[18]F]-2-fluoro-2-deoxy-D-glucose;[[18]F]-fluoromisonidazole;[[18]F]-fluorothymidine;16-alpha-[[18]F]-fluoroestradiol;and [[15]O]-water. The radiochemists are responsible for assuring the radiochemical purity and pharmaceutical quality of all products for in vivo studies and for compliance with all regulations regarding radiation and pharmaceutical safety.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-K)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
Fowler, Amy M; Clark, Amy S; Katzenellenbogen, John A et al. (2016) Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 57 Suppl 1:75S-80S
Kurland, Brenda F; Muzi, Mark; Peterson, Lanell M et al. (2016) Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. J Nucl Med 57:226-30
Muzi, Mark; Krohn, Kenneth A (2016) Imaging Hypoxia with ¹⁸F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis. J Nucl Med 57:497-8
Currin, Erin; Peterson, Lanell M; Schubert, Erin K et al. (2016) Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. J Natl Compr Canc Netw 14:144-7
Kurland, Brenda F; Peterson, Lanell M; Lee, Jean H et al. (2016) Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res :
Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2016) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med :
Link, Jeanne M (2015) Publish or perish…but where? What is the value of impact factors? Nucl Med Biol 42:426-7
Peck, M; Pollack, H A; Friesen, A et al. (2015) Applications of PET imaging with the proliferation marker [18F]-FLT. Q J Nucl Med Mol Imaging 59:95-104
Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2015) Effect of (18)F-FDG uptake time on lesion detectability in PET imaging of early stage breast cancer. Tomography 1:53-60
Rockne, Russell C; Trister, Andrew D; Jacobs, Joshua et al. (2015) A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET. J R Soc Interface 12:

Showing the most recent 10 out of 191 publications